X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
SHP2 (PTPN11), a cellular enzyme in the protein tyrosine phosphatase family, plays an important role in multiple forms of cancer and in regulating the immune system.
Lead Product(s): Vociprotafib,Sotorasib
Therapeutic Area: Oncology Product Name: RMC-4630
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $550.0 million Upfront Cash: $50.0 million
Deal Type: Termination December 07, 2022
Details:
First patient dosed in global phase 2 clinical trial evaluating the combination of RMC-4630 (SAR442720)and lumakras™ (sotorasib) in patients with advanced non-small-cell lung cancer.
Lead Product(s): Vociprotafib,Sotorasib
Therapeutic Area: Oncology Product Name: RMC-4630
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2022
Details:
Under the terms of the agreement, Sanofi will be responsible for sponsoring and operating the Phase 1/2 study, and jointly with Mirati, will oversee and share costs of the study.
Lead Product(s): Adagrasib,Vociprotafib
Therapeutic Area: Oncology Product Name: MRTX849
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 07, 2021
Details:
The ongoing Phase 1b/2 RMC-4630-02 trial is designed to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of RMC-4630 and cobimetinib in adult patients with relapsed/refractory solid tumors that harbor specific genomic mutations.
Lead Product(s): Vociprotafib,Cobimetinib
Therapeutic Area: Oncology Product Name: RMC-4630
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2020
Details:
Revolution Medicines dosed first patient in a multicenter Phase 1 clinical trial evaluating the combination of RMC-4630 (SAR442720), the company’s investigational SHP2 inhibitor, and pembrolizumab (Keytruda®), an anti-PD-1 antibody.
Lead Product(s): Vociprotafib,Pembrolizumab
Therapeutic Area: Oncology Product Name: RMC-4630
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Details:
The trial is an open-label, dose-escalation and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and efficacy of the combination of RMC-4630 and AMG 510 in patients with advanced solid tumors harboring the KRASG12C mutation.
Lead Product(s): Vociprotafib,Sotorasib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2020
Details:
Findings Support Plans to Expand Clinical Evaluation of RMC-4630, the Company’s Investigational SHP2 Inhibitor, to Include Combination with Anti-PD-1 Drug .
Lead Product(s): Vociprotafib,Cobimetinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2020
Details:
Revolution Medicine positioned to expand the horizon on KRAS with 4 programs. KRASG12C, KRASG13C, KRASG12D and NRASG12C with the first development candidate coming up this year.
Lead Product(s): Vociprotafib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 18, 2020
Details:
In this study RMC-4630 has shown reasonable tolerability and preliminary signs of clinical activity in patients with non-small cell lung cancer (NSCLC) harboring KRAS mutations, particularly KRASG12C.
Lead Product(s): Vociprotafib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
